Vol. 5, Issue 2, Part A (2023)

In the coming years, a new generation of adjuvants will be available thanks to small molecules' modulation of TLR4. Since many TLR4 modulators, such GLA and MPLA, have been granted clinical acceptance, the potential for TLR4 agonists as adjuvants or medications for cancer immunotherapy has been raised. The use of adjuvants with vaccines can improve immune response and specificity. This article provides a thorough summary of TLR4 agonists that have been created using synthetic or naturally occurring tiny molecules, and it shows how different molecular fragments affect action. Consequently, a discussion of how small molecule modification could alter how they act is presented.